Brought to you by 
Athenagen and Zapaq merge to form neurological presence
17 Jul 2006
Executive Summary
Private biotechs Athenagen (small-molecule nicotinic acetylcholine (nACh) receptor modulators) and Zapaq (founded in 2001; aspartic protease inhibitors for Alzheimer's disease) have agreed to merge, keeping the Athenagen name and focusing resources on CNS disorders. The transaction is expected to close before the end of August 2006.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Athenagen and Zapaq merge to form neurological presence
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice